CRM197 is a key component of many vaccine formulations utilized worldwide.
Prior to Fina Biosolutions' new method of production, the CRM197protein was manufactured by Corynebacterium diphtheriae at low yields or was available commercially at high cost. Ltd. access to the protein hindered vaccine development and increased vaccine production costs considerably, especially for emerging market manufacturers.
The recently-granted patent is for Fina Biosolutions' revolutionary new method of CRM197 expression, which produces the protein at very high yields without the need for Corynebacterium diphtheriae.
The CRM197 manufactured by this method is soluble, properly-folded and expressed in the cytoplasm of E. coli, a bacterium commonly used in biotechnology.
With this invention, low-cost production of a valuable vaccine component is now possible and opens the door to manufacturing conjugate vaccines at lower costs.
Corresponding applications have been filed and are issued or pending in many other countries.
The issuance of the United States patent 10,093,704 closely follows the allowances of corresponding applications in Australia, New Zealand and South Africa.
Fina Biosolutions markets CRM197 under the tradename EcoCRM, for E. coli CRM197.
The protein has been evaluated extensively in preclinical studies, including vaccines for infectious diseases, cancer, addiction treatment and Alzheimer's. EcoCRM is available for licensing.
Many vaccine components do not induce an immune response unless linked (conjugated) to a protein, such as CRM197. CRM197 is a widely used component of conjugate vaccines, including the world's best-selling vaccine, Prevnar13 (Pfizer's pneumococcal vaccine).
CRM197 is also a component of vaccines for Haemophilus influenzae b, meningococcal and many vaccines in development. CRM197 is a genetically detoxified diphtheria toxin.
Fina Biosolutions is a privately-owned R and D biotechnology company located in Rockville, MD. The company provides laboratory services and technology in the field of conjugate vaccines.
Chemistry developed by Fina Biosolutions scientists is used in GlaxoSmithKline's pneumococcal conjugate vaccine, Pfizer's meningococcal conjugate vaccine and others.
Fina Biosolutions and scientists collectively hold fourteen patents in the field of conjugate vaccines, with several currently used in some of the most important vaccines on the market.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer